Researchers published a proof-of-principle paper in the journal Science Immunology demonstrating just how precision medicine for inflammatory skin rashes might work.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), and National Institute on Minority Health and Health Disparities (NIMHD) are sponsoring a virtual workshop on Health Disparities in Osteoarthritis on Tuesday, July 12 – Wednesday, July 13, 2022, starting at 11:00 AM (ET) each day. The workshop will focus on combining behavioral and biomedical science to address personal, interpersonal, and societal influences that contribute to health disparities in osteoarthritis. Discussions will cover how understanding these disparities can lead to better health in osteoarthritis. Please visit the NIH Health Disparities in Osteoarthritis Workshop page
NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment for this common condition, osteoarthritis.
The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.